Mesoblast
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The last earnings update was 95 days ago. More info.
Add to Portfolio Compare Print
- Mesoblast has significant price volatility in the past 3 months.
MSB Share Price and Events
7 Day Returns
1 Year Returns
MSB Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Mesoblast (MSB) | -0.4% | -14.2% | -10.6% | -13.6% | -27.5% | -80.1% |
| AU Biotechs | -2.1% | -4.4% | 6.6% | 19.4% | 78.6% | 132.7% |
| AU Market | 0.7% | 4.7% | 6.7% | 1.6% | 24.9% | 4.2% |
1 Year Return vs Industry and Market
- MSB underperformed the Biotechs industry which returned 19.4% over the past year.
- MSB underperformed the Market in Australia which returned 1.6% over the past year.
MSB Value
Is Mesoblast undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Mesoblast. This is due to cash flow or dividend data being unavailable. The share price is A$1.175.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Mesoblast's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Mesoblast's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-09-30) in USD | $-0.10 |
| ASX:MSB Share Price ** | ASX (2019-02-19) in AUD | A$1.18 |
| ASX:MSB Share Price converted to USD reporting currency | Exchange rate (AUD/ USD) 0.713 | $0.84 |
| Global Biotechs Industry PE Ratio | Median Figure of 74 Publicly-Listed Biotechs Companies | 23.16x |
| Australia Market PE Ratio | Median Figure of 559 Publicly-Listed Companies | 15.9x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Mesoblast.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ASX:MSB Share Price ÷ EPS (both in USD) = 0.84 ÷ -0.10 |
-8.32x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Mesoblast is loss making, we can't compare its value to the Global Biotechs industry average.
- Mesoblast is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does
Mesoblast's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -8.32x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts |
67.5%per year |
| Global Biotechs Industry PEG Ratio | Median Figure of 57 Publicly-Listed Biotechs Companies | 1.55x |
| Australia Market PEG Ratio | Median Figure of 361 Publicly-Listed Companies | 1.43x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Mesoblast, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Mesoblast's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-09-30) in USD | $1.10 |
| ASX:MSB Share Price * | ASX (2019-02-19) in AUD | A$1.18 |
| ASX:MSB Share Price converted to USD reporting currency | Exchange rate (AUD/ USD) 0.713 | $0.84 |
| Australia Biotechs Industry PB Ratio | Median Figure of 47 Publicly-Listed Biotechs Companies | 3.14x |
| Australia Market PB Ratio | Median Figure of 1,664 Publicly-Listed Companies | 1.64x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ASX:MSB Share Price ÷ Book Value per Share (both in USD) = 0.84 ÷ 1.10 |
0.76x |
* Primary Listing of Mesoblast.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Mesoblast is good value based on assets compared to the AU Biotechs industry average.
Value checks
We assess Mesoblast's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Mesoblast has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
MSB Future Performance
How is Mesoblast expected to perform in the next 1 to 3 years based on estimates from 7 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Mesoblast's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
- Mesoblast's earnings growth is expected to exceed the Australia market average.
- Mesoblast's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ASX:MSB Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts | 67.5% |
| ASX:MSB Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts | 59.9% |
| Australia Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 10% |
| Australia Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 7.9% |
| Australia Market Earnings Growth Rate | Market Cap Weighted Average | 5.9% |
| Australia Market Revenue Growth Rate | Market Cap Weighted Average | 2.4% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-06-30 | 804 | 363 | 2 | |
| 2022-06-30 | 419 | -6 | 3 | |
| 2021-06-30 | 326 | -77 | -70 | 3 |
| 2020-06-30 | 65 | -24 | -95 | 4 |
| 2019-06-30 | 20 | -66 | -90 | 6 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-09-30 | 28 | -74 | -48 |
| 2018-06-30 | 17 | -75 | -35 |
| 2018-03-31 | 16 | -78 | -42 |
| 2017-12-31 | 16 | -84 | -30 |
| 2017-09-30 | 3 | -95 | -64 |
| 2017-06-30 | 2 | -95 | -77 |
| 2017-03-31 | 29 | -90 | -1 |
| 2016-12-31 | 32 | -86 | -8 |
| 2016-09-30 | 35 | -81 | -11 |
| 2016-06-30 | 43 | -88 | -4 |
| 2016-03-31 | 20 | -97 | -83 |
| 2015-12-31 | 20 | -98 | -88 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
All data from Mesoblast Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-06-30 | ||||
| 2022-06-30 | ||||
| 2021-06-30 | -0.16 | -0.16 | -0.16 | 1.00 |
| 2020-06-30 | -0.04 | 0.02 | -0.10 | 2.00 |
| 2019-06-30 | -0.18 | -0.18 | -0.18 | 2.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-09-30 | -0.10 |
| 2018-06-30 | -0.08 |
| 2018-03-31 | -0.09 |
| 2017-12-31 | -0.07 |
| 2017-09-30 | -0.16 |
| 2017-06-30 | -0.19 |
| 2017-03-31 | -0.00 |
| 2016-12-31 | -0.02 |
| 2016-09-30 | -0.03 |
| 2016-06-30 | -0.01 |
| 2016-03-31 | -0.24 |
| 2015-12-31 | -0.26 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Mesoblast will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Future performance checks
We assess Mesoblast's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Mesoblast has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
MSB Past Performance
How has Mesoblast performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Mesoblast does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Mesoblast's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Mesoblast's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Mesoblast Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-09-30 | 27.80 | -47.77 | 22.51 | 69.05 |
| 2018-06-30 | 17.34 | -35.29 | 21.91 | 65.93 |
| 2018-03-31 | 16.21 | -41.64 | 23.84 | 64.33 |
| 2017-12-31 | 16.04 | -30.29 | 23.32 | 61.46 |
| 2017-09-30 | 3.19 | -64.04 | 22.56 | 60.28 |
| 2017-06-30 | 2.41 | -76.82 | 23.01 | 58.91 |
| 2017-03-31 | 28.73 | -1.34 | 21.69 | 57.37 |
| 2016-12-31 | 31.97 | -8.49 | 21.59 | 55.46 |
| 2016-09-30 | 35.43 | -10.77 | 22.42 | 52.93 |
| 2016-06-30 | 42.55 | -4.13 | 22.50 | 50.01 |
| 2016-03-31 | 19.85 | -83.00 | 24.99 | 54.09 |
| 2015-12-31 | 19.94 | -88.30 | 26.31 | 55.52 |
| 2015-09-30 | 20.31 | -93.86 | 28.13 | 60.85 |
| 2015-06-30 | 19.76 | -96.24 | 29.54 | 62.65 |
| 2015-03-31 | 21.25 | -84.77 | 26.05 | 55.61 |
| 2014-12-31 | 23.50 | -84.42 | 24.85 | 55.26 |
| 2014-09-30 | 26.12 | -75.37 | 24.15 | 50.82 |
| 2014-06-30 | 23.39 | -75.53 | 24.40 | 50.93 |
| 2014-03-31 | 30.10 | -67.78 | 23.32 | 49.38 |
| 2013-12-31 | 35.50 | -57.90 | 21.45 | 46.13 |
| 2013-09-30 | 37.41 | -56.40 | 21.38 | 45.80 |
| 2013-06-30 | 31.78 | -56.45 | 20.91 | 43.79 |
| 2013-03-31 | 35.78 | -60.61 | 25.47 | 47.58 |
| 2012-12-31 | 35.35 | -56.90 | 27.11 | 45.26 |
| 2012-09-30 | 37.52 | -65.34 | 28.10 | 41.78 |
| 2012-06-30 | 39.18 | -72.82 | 24.62 | 37.89 |
| 2012-03-31 | 38.45 | -61.06 | 24.55 | 31.21 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Mesoblast has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Mesoblast has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Mesoblast improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Mesoblast's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Mesoblast has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
MSB Health
How is Mesoblast's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Mesoblast's finances.
The net worth of a company is the difference between its assets and liabilities.
- Mesoblast is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Mesoblast's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Mesoblast Company Filings, last reported 4 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-09-30 | 527.60 | 61.16 | 55.14 |
| 2018-06-30 | 546.01 | 59.40 | 37.76 |
| 2018-03-31 | 556.14 | 31.42 | 59.54 |
| 2017-12-31 | 575.61 | 0.00 | 47.39 |
| 2017-09-30 | 559.59 | 0.00 | 62.94 |
| 2017-06-30 | 516.77 | 0.00 | 45.76 |
| 2017-03-31 | 540.40 | 0.00 | 69.12 |
| 2016-12-31 | 510.52 | 0.00 | 33.90 |
| 2016-09-30 | 509.87 | 0.00 | 60.36 |
| 2016-06-30 | 528.16 | 0.00 | 80.94 |
| 2016-03-31 | 478.94 | 0.00 | 99.93 |
| 2015-12-31 | 492.75 | 0.00 | 120.78 |
| 2015-09-30 | 452.83 | 0.00 | 77.76 |
| 2015-06-30 | 467.99 | 0.00 | 110.70 |
| 2015-03-31 | 478.60 | 0.00 | 122.09 |
| 2014-12-31 | 478.60 | 0.00 | 122.09 |
| 2014-09-30 | 512.53 | 0.00 | 149.14 |
| 2014-06-30 | 539.18 | 0.00 | 185.22 |
| 2014-03-31 | 530.08 | 0.00 | 182.09 |
| 2013-12-31 | 570.37 | 0.00 | 226.81 |
| 2013-09-30 | 589.12 | 0.00 | 297.98 |
| 2013-06-30 | 576.98 | 0.00 | 291.84 |
| 2013-03-31 | 656.01 | 0.00 | 331.82 |
| 2012-12-31 | 470.87 | 0.00 | 185.49 |
| 2012-09-30 | 470.58 | 0.00 | 185.37 |
| 2012-06-30 | 490.15 | 0.00 | 210.44 |
| 2012-03-31 | 496.50 | 0.00 | 213.17 |
- Mesoblast's level of debt (11.6%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 11.6% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Mesoblast has less than a year of cash runway based on current free cash flow.
- Mesoblast has less than a year of cash runway if free cash flow continues to reduce at historical rates of -8.7% each year.
Financial health checks
We assess Mesoblast's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Mesoblast has a total score of 2/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
MSB Dividends
What is Mesoblast's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
A$2,000 of
Mesoblast
shares you are expected to receive
A$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Mesoblast's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Mesoblast's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 22 Stocks | 2.4% |
| Australia Market Average Dividend Yield | Market Cap Weighted Average of 420 Stocks | 4.4% |
| Australia Minimum Threshold Dividend Yield | 10th Percentile | 1.6% |
| Australia Bottom 25% Dividend Yield | 25th Percentile | 2.7% |
| Australia Top 25% Dividend Yield | 75th Percentile | 6.1% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-06-30 | ||
| 2022-06-30 | ||
| 2021-06-30 | ||
| 2020-06-30 | ||
| 2019-06-30 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Mesoblast has not reported any payouts.
- Unable to verify if Mesoblast's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Mesoblast's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Mesoblast afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Mesoblast has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
MSB Management
CEO
| COMPENSATION | $2,033,623 |
| AGE | 61 |
| TENURE AS CEO | 8.1 years |
CEO Bio
Prof. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACRA, FTSE has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesoblast, Inc. He serves as a Director of Transplantation Immunology at Columbia University's New York. Prof. Itescu founded Mesoblast Limited in 2004 and served as its Chief Scientific Advisor since June 2004. He serves as Professor of Medicine at the University of Melbourne and has an outstanding international reputation in research and development in biotechnology. Prof. Itescu is on the Medical Faculties of both Columbia University in NewYork and Melbourne University. He is a faculty member of Monash University. He has established an outstanding international reputation in the fields of Cell Biology, immunology, autoimmune diseases, organ transplantation and heart failure. In these areas of focus, Prof. Itescu has gained broad experience, from basic research in the laboratory through to new drug development and clinical evaluation. He serves as the Chairman and Member of Scientific Advisory Board at Mesoblast Limited. Prof. Itescu has been an Executive Director of Mesoblast Limited since 2007 and served as its director since June 2004 until 2007. He serves as an Executive Director of Mesoblast, Inc. Prof. Itescu is a member of numerous national and international scientific bodies and professional societies, has consulted globally for many international pharmaceutical companies and has been an advisor to biotechnology and health care investment groups. Prof. Itescu served as a Member of Executive Committee of Alliance for Regenerative Medicine. He served as a Director of Diversa Limited (formelry Ambri Ltd.) from September 18, 2003 to December 20, 2006 and Zenyth Therapeutics Ltd. (formerly Amrad Corp. Ltd.) from July 17, 2003 to November 2006. He has served on the board of directors of several publicly listed life sciences companies. Prof. Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. In 2011, Prof. Itescu was named BioSpectrum Asia Person of the Year. In 2013, he received the inaugural Key Innovator Award from the Vatican’s Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. Prof. Itescu holds a Medical Degree from Monash University and received his Specialty Training in Internal Medicine and Immunology/Rheumatology from New York University.
CEO Compensation
- Silviu's compensation has increased whilst company is loss making.
- Silviu's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure
Average tenure and age of the Mesoblast management team in years:
- The average tenure for the Mesoblast management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team
Silviu Itescu
Founder
$2M
61
8.1 yrs
Donna Skerrett
Chief Medical Officer
61
8.1 yrs
Roger Brown
Head of Spinal Orthopedic Disorders
3.3 yrs
Michael Schuster
Head of Pharma Partnering
41
Kenneth Borow
Executive
70
Josh Muntner
Chief Financial Officer
49
0.8 yrs
Jon Symonds
Head of Corporate Finance & Strategy
59
Peter Howard
General Counsel & Corporate Executive
50
7.6 yrs
Julie Meldrum
Global Head of Corporate Communications
Paul Simmons
Head of Research & New Product Development
59
8.1 yrs
Board of Directors Tenure
Average tenure and age of the Mesoblast board of directors in years:
- The average tenure for the Mesoblast board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Brian Jamieson
Non-Executive Chairman
$270K
74
11.3 yrs
Silviu Itescu
Founder
$2M
61
Bill Burns
Non-Executive Vice Chairman
$180K
71
3.1 yrs
Donal O’Dwyer
Non-Executive Director
$147K
65
14.4 yrs
Michael Spooner
Non-Executive Director
$147K
61
14.4 yrs
Eric Rose
Non Executive Director
$133K
67
5.8 yrs
Bob Graham
Member of Scientific Advisory Board
Henry Krum
Member of Scientific Advisory Board
Joseph Lane
Member of Scientific Advisory Board
Richard Gilbert
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (A$) | Value (A$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 10. Feb 19 | Sell | Capital Research and Management Company | Company | 08. Mar 18 | 07. Feb 19 | -2,721,380 | A$1.22 | A$-3,306,476 | ||
| 15. Oct 18 | Sell | M&G Investment Management Limited | Company | 14. Dec 17 | 11. Sep 18 | -2,932,191 | A$1.49 | A$-4,367,871 | ||
| 15. Oct 18 | Buy | M&G Investment Management Limited | Company | 21. May 18 | 19. Jul 18 | 1,796,507 | A$1.44 | A$2,578,058 | ||
| 09. Mar 18 | Buy | Capital Research and Management Company | Company | 24. Mar 15 | 07. Mar 18 | 14,838,893 | A$1.84 | A$27,288,723 | ||
Management checks
We assess Mesoblast's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Mesoblast has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
MSB News
Simply Wall St News
Does Mesoblast Limited's (ASX:MSB) CEO Pay Compare Well With Peers?
In 2011 Silviu Itescu was appointed CEO of Mesoblast Limited (ASX:MSB). … This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Silviu Itescu's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleCan We See Significant Insider Ownership On The Mesoblast Limited (ASX:MSB) Share Register?
A look at the shareholders of Mesoblast Limited (ASX:MSB) can tell us which group is most powerful. … Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'.
Simply Wall St - – Full articleWhat Does Mesoblast Limited's (ASX:MSB) Ownership Structure Look Like?
Today, I will be analyzing Mesoblast Limited’s (ASX:MSB) recent ownership structure, an important but not-so-popular subject among individual investors. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.
Simply Wall St - – Full articleWhat Are The Drivers Of Mesoblast Limited's (ASX:MSB) Risks?
Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.
Simply Wall St - – Full articleWhen Can We Expect A Profit From Mesoblast Limited (ASX:MSB)?
With the latest financial year loss of -US$76.81m and a trailing-twelve month of -US$41.64m, the US$696.58m market-cap alleviates its loss by moving closer towards its target of breakeven? … The most pressing concern for investors is MSB’s path to profitability – when will it breakeven. … In this article, I will touch on the expectations for MSB’s growth and when analysts expect the company to become profitable
Simply Wall St - – Full articleMesoblast Limited (ASX:MSB) Is Expected To Breakeven
Many investors are wondering the rate at which MSB will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for MSB, its year of breakeven and its implied growth rate. … Next Steps: This article is not intended to be a comprehensive analysis on MSB, so if you are interested in understanding the company at a deeper level, take a look at MSB’s company page on Simply Wall St. … Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
Simply Wall St - – Full articleWho Really Owns Mesoblast Limited (ASX:MSB)?
In this article, I will take a quick look at Mesoblast Limited’s (ASX:MSB) recent ownership structure – an unconventional investing subject, but an important one. … Private Company Ownership Potential investors in MSB should also look at another important group of investors: private companies, with a stake of 2.05%, who are primarily invested because of strategic and capital gain interests. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.
Simply Wall St - – Full articleHow Mesoblast Limited (ASX:MSB) Can Impact Your Portfolio Volatility
A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … Thus, we can expect MSB to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books.
Simply Wall St - – Full articleBullish Mesoblast Limited (ASX:MSB) Insiders Ramp Up Investment In Stock
Insiders' net buying activities seem to bolster the idea of growth moving forward. … An alternative reason for recent trades could be insiders taking advantage of the share price volatility. … Next Steps: Mesoblast’s net buying tells us the stock is in favour with some insiders, though negative growth in expected earnings contests this assumption, whereas a highly volatile share price could be the driver to buy.
Simply Wall St - – Full articleMesoblast Limited's (ASX:MSB) Shift From Loss To Profit
Many investors are wondering the rate at which MSB will turn a profit, with the big question being “when will the company breakeven?” In this article, I will touch on the expectations for MSB’s growth and when analysts expect the company to become profitable. … Working backwards from analyst estimates, it turns out that they expect the company to grow 64.30% year-on-year, on average, which is rather optimistic! … For a more comprehensive look at MSB, take a look at MSB’s company page on Simply Wall St.
Simply Wall St - – Full articleMSB Company Info
Map
Description
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company’s products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Details
| Name: | Mesoblast Limited |
| MSB | |
| Exchange: | ASX |
| Founded: | 2004 |
| A$576,822,032 | |
| 495,126,208 | |
| Website: | http://www.mesoblast.com |
| Address: |
Mesoblast Limited 55 Collins Street, Level 38, Melbourne, Victoria, 3000, Australia |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ASX | MSB | Ordinary Shares | Australian Securities Exchange | AU | AUD | 16. Dec 2004 | |
| OTCPK | MEOB.F | Ordinary Shares | Pink Sheets LLC | US | USD | 16. Dec 2004 | |
| DB | LWB | Ordinary Shares | Deutsche Boerse AG | DE | EUR | 16. Dec 2004 | |
| CHIA | MSB | Ordinary Shares | Chi-X Australia | AU | AUD | 16. Dec 2004 | |
| NasdaqGS | MESO | SPON ADR EACH REP 5 SHS | Nasdaq Global Select | US | USD | 15. Dec 2005 | |
| DB | LWBA | SPON ADR EACH REP 5 SHS | Deutsche Boerse AG | DE | EUR | 15. Dec 2005 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/02/19 10:31 |
| End of day share price update: | 2019/02/19 00:00 |
| Last estimates confirmation: | 2019/02/06 |
| Last earnings filing: | 2018/11/16 |
| Last earnings reported: | 2018/09/30 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
